The Pancreatic Cancer Action Network, or PanCAN, and the Global Coalition for Adaptive Research formed a strategic alliance to further advance research efforts for pancreatic cancer.
The New York Proton Center and the WiTT Group Inc. formed a strategic partnership to help patients navigate the non-clinical challenges of cancer treatment.
FDA has approved Welireg (belzutifan) for patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
FDA has approved Padcev (enfortumab vedotin-ejfv) in combination with Keytruda (pembrolizumab) for patients with locally advanced or metastatic urothelial cancer (la/mUC).
The European Commission has granted marketing authorization for Jemperli (dostarlimab) in combination with carboplatin-paclitaxel, for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.
Infinimmune and Grid Therapeutics formed a partnership to collaborate on identifying new antibody drug candidates for non-small cell lung cancer.
Elektrofi Inc., a biopharmaceutical formulation technology has entered a multi-target worldwide research collaboration and license agreement with Janssen Biotech Inc., a Johnson & Johnson company.
FDA approved Welireg (belzutifan) for patients with advanced renal cell carcinoma following a PD-1 or PD-L1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor.
FDA approved Iwilfin (eflornithine) to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.
AnHeart Therapeutics and Foundation Medicine Inc. have entered a strategic collaboration for the development and regulatory approval of Foundation Medicine’s tissue- and liquid-based comprehensive genomic profiling tests, FoundationOne CDx and FoundationOne Liquid CDx, as companion diagnostics for AnHeart’s investigational next-generation ROS1 inhibitor, taletrectinib, in the United States.
